What the FDA labels say about taking them together
Cyclobenzaprine and meperidine
Cyclobenzaprine's FDA label of February 21, 2025 names meperidine in its warnings section, and meperidine's label names cyclobenzaprine too. The meperidine label: “The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.”
Check it at the source: the cyclobenzaprine FDA label on DailyMed (effective February 21, 2025, Jubilant Cadista Pharmaceuticals Inc.); the meperidine FDA label on DailyMed (effective November 29, 2025, EPIC PHARMA, LLC).
What does the cyclobenzaprine label say about meperidine?
Cyclobenzaprine label, warningsWARNINGS Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with cyclobenzaprine hydrochloride when used in combination with other drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors.
Cyclobenzaprine Hydrochloride label (Teva Pharmaceuticals USA, Inc., May 31, 2024), drug interactionsPostmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [see Warnings and Precautions ( 5.1 )].
Tonmya label (Tonix Medicines, Inc., August 14, 2026), drug interactionsPostmarketing cases of serotonin syndrome have been reported with the concomitant use of oral cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [see Warnings and Precautions (5.2) ].
Source: FDA drug label (Cyclobenzaprine Hydrochloride, NDA021777), Teva Pharmaceuticals USA, Inc., effective May 31, 2024 (SPL set ca74d27a-f7c6-462d-a913-1cfa061bd8f3), via openFDA
Source: FDA drug label (Tonmya, NDA219428), Tonix Medicines, Inc., effective August 14, 2026 (SPL set 6fa59588-ce9b-48cf-8c5f-725a448f8571), via openFDA
Source: FDA drug label (Cyclobenzaprine Hydrochloride), Jubilant Cadista Pharmaceuticals Inc., effective February 21, 2025 (SPL set 592871f6-0eb2-4624-9e10-bd8bf767c002), via openFDA; the full label on DailyMed
What does the meperidine label say about cyclobenzaprine?
Meperidine label, drug interactionsSerotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. … serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue)
Meperidine label, warnings and precautionsSerotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), St John’s wort, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and drugs that impair metabolism of serotonin (including MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see Drug Interactions (7) ].
Source: FDA drug label (Demerol, NDA021171), Hospira, Inc., effective July 20, 2026 (SPL set b31d1308-28c3-43f4-e0a6-2f3ed76b8975), via openFDA
Source: FDA drug label (Meperidine Hydrochloride), EPIC PHARMA, LLC, effective November 29, 2025 (SPL set fae5cc34-5917-4445-9516-25f97ffca8db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclobenzaprine | Meperidine | |
|---|---|---|
| Labeled for | Muscle spasms and spasticity, Nerve pain and fibromyalgia | Pain |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0171 per tablet 10 mg tablet | $0.157 per mL 50 mg/5 mL solution |
| Shortage now | No current entry | Listed; available |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once